Title

The dynamics of CD147 in Alzheimer's disease development and pathology

Document Type

Journal Article

Publisher

IOS Press

Faculty

Faculty of Computing, Health and Science

School

School of Medical Sciences / Centre of Excellence for Alzheimer's Disease Research and Care

RAS ID

12627

Comments

This article was originally published as: Kanyenda, L. J., Verdile, G. , Boulos, S., Krishnaswamy, S. , Taddei, K. , Meloni, B., Mastaglia, F., & Martins, R. N. (2011). The dynamics of CD147 in Alzheimer's disease development and pathology. Journal of Alzheimer's Disease, 26(4), 593-605. Original article available here

Abstract

CD147, also known as basigin, EMMPRIN, neurothelin, TCSF, M6, HT7, OX47, or gp42, is a transmembrane glycoprotein of the immunoglobulin super-family. It is expressed in many neuronal and non-neuronal tissues including the hippocampus, pre-frontal cortex thyroid, heart, early erythroid, amygdala, and placenta. This protein is involved in various cellular and biological functions, such as lymphocyte migration and maturation, tissue repair cancer progression, T and B lymphocyte activation, and induction of extracellular matrix metalloproteinase. The CD147 protein interacts with other proteins such as cyclophilin A (CyPA), Cyclophilin B (CyPB), sterol carrier protein (SCP), caveolin-1 and integrins, and can influence amyloid-beta (A beta) peptide levels, a protein that is central to Alzheimer's disease (AD) pathogenesis. Mechanisms by which CD147 regulate A beta levels remain unclear, thus in this review we discuss its involvement in A beta production and clearance and potential mechanisms by which controlling CD147 levels could impact on A beta accumulation and AD pathogenesis.

DOI

10.3233/JAD-2011-110584

 

Link to publisher version (DOI)

10.3233/JAD-2011-110584